MCE Enfuvirtide 99.81%

Enfuvirtide, also known as T20 or DP178, is a synthetic 36-amino acid peptide and a highly specific HIV-1 fusion inhibitor targeting the gp41 subunit of the viral envelope glycoprotein. It is widely used in research to study HIV entry mechanisms, antiviral drug resistance, and combination antiretroviral therapy development.

Enfuvirtide functions by binding to the heptad repeat region of gp41, blocking the conformational changes required for viral and host membrane fusion. This prevents the formation of the fusion pore necessary for HIV-1 to enter CD4⁺ host cells, thereby inhibiting the earliest step of the viral life cycle.

Mechanism of Action

Enfuvirtide interrupts HIV-1 infection at the membrane fusion stage by preventing the folding of gp41 into its fusion-active structure. This blocks viral entry before the release of viral RNA into the host cell.

In cell-cell fusion assays, Enfuvirtide demonstrates strong inhibitory activity with an IC₅₀ of 23 ± 6 nM, confirming its potency as a fusion inhibitor.

It also shows synergy with other antiretroviral agents such as AZT, Efavirenz, Indinavir, and IFN-λs, significantly reducing HIV p24 antigen production and Gag gene expression in macrophage infection models.

Chemical & Physical Properties

• Molecular Formula: C204H301N51O64
• Molecular Weight: 4491.88
• Purity: 99.93%
• Appearance: White to off-white solid
• Sequence:
  Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH₂
• Abbreviated Sequence:
  Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH₂

In Vitro and In Vivo Performance

In vitro testing confirms Enfuvirtide’s ability to inhibit HIV-1 fusion and replication in macrophages by suppressing both p24 antigen production and Gag gene expression.

In vivo, Enfuvirtide has a reported biological half-life (T½) of 3.8 hours, making it suitable for pharmacokinetic and antiviral efficacy studies.

Storage & Stability

• Powder Storage:
  -80°C: stable for 2 years
  -20°C: stable for 1 year
• In Solution:
  -80°C: stable for 6 months
  -20°C: stable for 1 month
• Store sealed and protected from moisture.

Applications

Enfuvirtide is commonly used in:

• HIV-1 viral entry inhibition studies

• gp41 structural and fusion mechanism research

• Antiviral drug screening

• HIV drug resistance modeling

• Combination antiretroviral therapy research

• Macrophage and immune response studies

Enfuvirtide (T20; DP178) is a high-purity, research-grade HIV-1 fusion inhibitor peptide with well-documented potency and biological activity. Its precise mechanism of action, strong in vitro validation, and established relevance in HIV resistance and antiviral studies make it an essential tool for HIV virology, antiviral drug discovery, and molecular immunology research.